Antiplatelet | Beta-blockers | ACEI/ARB | Statins | ||
Pensioners group versus control group | Level change (%) | −1.790 (1.24) | −1.021 (0.97) | −6.792 (6.35)** | −8.293 (5.61)** |
Slope change (%) | 0.004 (0.50) | 0.000 (0.03) | 0.023 (3.84)** | 0.031 (3.67)** | |
Time to counterfactual adherence rates for pensioners (months) | 15.4 | 17.9 | >20.7 | 18.4 | |
R2 | 0.97 | 0.96 | 0.92 | 0.97 | |
Middle-income to high-income group versus control group | Level change (%) | −1.120 (0.54) | −2.295 (1.41) | 0.066 (0.04) | −7.806 (3.57)** |
Slope change (%) | 0.010 (0.83) | 0.028 (3.03)** | −0.001 (0.17) | 0.044 (3.50)** | |
Time to counterfactual adherence rates for middle-income to high-income population (months) | 12.4 | 12.0 | 11.7 | 13.6 | |
R2 | 0.73 | 0.68 | 0.64 | 0.76 |
n=312
Antiplatelet, acetyl salicylic acid; ACEI/ARB, ACE inhibitors and angiotensin II receptor blockers.
t-ratios in parentheses *p<0.05; **p<0.01.